Serum sEV LOXL2 can reflect a hypoxic and aggressive tumor type and can serve as an alternative to tissue LOXL2 as an independent prognostic factor of overall survival for patients with HNSCC. This evidence concerns the gene LOXL2 and head and neck squamous cell carcinoma.